Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provide… Read more
Co-Diagnostics, Inc. Common Stock (CODX) - Total Liabilities
Latest total liabilities as of September 2025: $4.91 Million USD
Based on the latest financial reports, Co-Diagnostics, Inc. Common Stock (CODX) has total liabilities worth $4.91 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Co-Diagnostics, Inc. Common Stock - Total Liabilities Trend (2014–2024)
This chart illustrates how Co-Diagnostics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Co-Diagnostics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Co-Diagnostics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DRC Systems India Limited
NSE:DRCSYSTEMS
|
India | ₹406.32 Million |
|
DUG Foodtech AB (publ)
ST:VUXEN
|
USA | Skr38.20 Million |
|
Grey Cloak Tech Inc
OTCQB:HYEX
|
USA | $2.13 Million |
|
California First National Bancorp
OTCQX:CFNB
|
USA | $24.79 Million |
|
Ravelin Properties REIT
TO:RPR-UN
|
Canada | CA$1.22 Billion |
|
Glacier Media Inc
PINK:GLMFF
|
USA | $100.66 Million |
|
Toppoint Holdings Inc.
NYSE MKT:TOPP
|
USA | $1.55 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Co-Diagnostics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Co-Diagnostics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Co-Diagnostics, Inc. Common Stock (2014–2024)
The table below shows the annual total liabilities of Co-Diagnostics, Inc. Common Stock from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.69 Million | +4.09% |
| 2023-12-31 | $9.31 Million | +8.65% |
| 2022-12-31 | $8.57 Million | -66.48% |
| 2021-12-31 | $25.56 Million | +462.89% |
| 2020-12-31 | $4.54 Million | +849.80% |
| 2019-12-31 | $478.07K | -81.70% |
| 2018-12-31 | $2.61 Million | +221.75% |
| 2017-12-31 | $811.80K | -81.08% |
| 2016-12-31 | $4.29 Million | +182.58% |
| 2015-12-31 | $1.52 Million | +1152.55% |
| 2014-12-31 | $121.22K | -- |